1. Home
  2. RGLD vs MRNA Comparison

RGLD vs MRNA Comparison

Compare RGLD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royal Gold Inc.

RGLD

Royal Gold Inc.

HOLD

Current Price

$266.05

Market Cap

22.2B

Sector

Industrials

ML Signal

HOLD

Logo Moderna Inc.

MRNA

Moderna Inc.

HOLD

Current Price

$50.81

Market Cap

19.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGLD
MRNA
Founded
1981
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.2B
19.7B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
RGLD
MRNA
Price
$266.05
$50.81
Analyst Decision
Hold
Hold
Analyst Count
5
12
Target Price
$249.60
$34.27
AVG Volume (30 Days)
1.1M
5.3M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
0.72%
N/A
EPS Growth
32.74
21.77
EPS
6.69
N/A
Revenue
$1,030,471,000.00
$19,263,000,000.00
Revenue This Year
$93.18
$8.74
Revenue Next Year
$4.61
$16.18
P/E Ratio
$39.71
N/A
Revenue Growth
43.24
4.29
52 Week Low
$150.75
$22.28
52 Week High
$306.25
$59.55

Technical Indicators

Market Signals
Indicator
RGLD
MRNA
Relative Strength Index (RSI) 56.17 50.91
Support Level $253.20 $47.61
Resistance Level $305.47 $54.94
Average True Range (ATR) 8.91 2.53
MACD 4.14 -0.21
Stochastic Oscillator 84.18 50.66

Price Performance

Historical Comparison
RGLD
MRNA

About RGLD Royal Gold Inc.

Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: